-
Je něco špatně v tomto záznamu ?
Blood biomarker panel recommended for personalized prediction, prognosis, and prevention of complications associated with abdominal aortic aneurysm
J. Molacek, V. Treska, J. Zeithaml, I. Hollan, O. Topolcan, L. Pecen, D. Slouka, M. Karlikova, R. Kucera,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
NV15-32727A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
BioMedCentral Open Access
od 2012
PubMed Central
od 2010 do Před 1 rokem
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2011-01-01
- Publikační typ
- časopisecké články MeSH
The aim of the study was to evaluate the ability of following biomarkers as diagnostic tools and risk predictors of AAA: C-reactive protein, interleukin-6, pentraxin-3, galectin-3, procollagen type III N-terminal peptide, C-terminal telopeptide of type I collagen, high-sensitive troponin I, and brain natriuretic peptide. Seventy-two patients with an AAA and 100 healthy individuals were enrolled into the study. We assessed individual biomarker performance and correlation between the AAA diameter and biomarker levels, and also, a multivariate logistic regression was used to design a possible predictive model of AAA growth and rupture risk. We identified following four parameters with the highest potential to find a useful place in AAA diagnostics: galectin-3, pentraxin-3, interleukin-6, and C-terminal telopeptide of type I. The best biomarkers in our evaluation (galectin-3 and pentraxin-3) were AAA diameter-independent. With the high AUC and AAA diameter correlation, the high-sensitive troponin I can be used as an independent prognostic biomarker of the upcoming heart complications in AAA patients. Authors recommend to add biomarkers as additional parameters to the current AAA patient management. Main addition value of biomarkers is in the assessment of the AAA with the smaller diameter. Elevated biomarkers can change the treatment decision, which would be done only based on AAA diameter size. The best way how to manage the AAA patients is to create a reliable predictive model of AAA growth and rupture risk. A created multiparameter model gives very promising results with the significantly higher efficiency compared with the use of the individual biomarkers.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19036000
- 003
- CZ-PrNML
- 005
- 20201109151211.0
- 007
- ta
- 008
- 191007s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13167-019-00173-2 $2 doi
- 035 __
- $a (PubMed)31258818
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Molacek, Jiri $u 1Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
- 245 10
- $a Blood biomarker panel recommended for personalized prediction, prognosis, and prevention of complications associated with abdominal aortic aneurysm / $c J. Molacek, V. Treska, J. Zeithaml, I. Hollan, O. Topolcan, L. Pecen, D. Slouka, M. Karlikova, R. Kucera,
- 520 9_
- $a The aim of the study was to evaluate the ability of following biomarkers as diagnostic tools and risk predictors of AAA: C-reactive protein, interleukin-6, pentraxin-3, galectin-3, procollagen type III N-terminal peptide, C-terminal telopeptide of type I collagen, high-sensitive troponin I, and brain natriuretic peptide. Seventy-two patients with an AAA and 100 healthy individuals were enrolled into the study. We assessed individual biomarker performance and correlation between the AAA diameter and biomarker levels, and also, a multivariate logistic regression was used to design a possible predictive model of AAA growth and rupture risk. We identified following four parameters with the highest potential to find a useful place in AAA diagnostics: galectin-3, pentraxin-3, interleukin-6, and C-terminal telopeptide of type I. The best biomarkers in our evaluation (galectin-3 and pentraxin-3) were AAA diameter-independent. With the high AUC and AAA diameter correlation, the high-sensitive troponin I can be used as an independent prognostic biomarker of the upcoming heart complications in AAA patients. Authors recommend to add biomarkers as additional parameters to the current AAA patient management. Main addition value of biomarkers is in the assessment of the AAA with the smaller diameter. Elevated biomarkers can change the treatment decision, which would be done only based on AAA diameter size. The best way how to manage the AAA patients is to create a reliable predictive model of AAA growth and rupture risk. A created multiparameter model gives very promising results with the significantly higher efficiency compared with the use of the individual biomarkers.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Treska, Vladislav $u 1Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Zeithaml, Jan $u 1Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Hollan, Ivana $u 2Department of Rheumatology, Hospital for Rheumatic Diseases, 2609 Lillehammer, Norway. 3Department of Research, Innlandet Hospital Trust, Brumunddal, Norway. 4Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA USA.
- 700 1_
- $a Topolcan, Ondrej $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Pecen, Ladislav $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Slouka, David $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Karlikova, Marie $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Kucera, Radek $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic. 6Department of Immunochemistry Diagnostics, University Hospital Pilsen, Dr. E. Benese 1128/13, 305 99 Pilsen, Czech Republic.
- 773 0_
- $w MED00181668 $t The EPMA journal $x 1878-5077 $g Roč. 10, č. 2 (2019), s. 125-135
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31258818 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20201109151210 $b ABA008
- 999 __
- $a ind $b bmc $g 1452660 $s 1074550
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 10 $c 2 $d 125-135 $e 20190603 $i 1878-5077 $m The EPMA journal $n EPMA J $x MED00181668
- GRA __
- $a NV15-32727A $p MZ0
- LZP __
- $a Pubmed-20191007